22-28712013-C-G
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_007194.4(CHEK2):āc.688G>Cā(p.Ala230Pro) variant causes a missense change. The variant allele was found at a frequency of 0.00000248 in 1,610,176 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_007194.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000663 AC: 1AN: 150906Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251330Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135850
GnomAD4 exome AF: 0.00000206 AC: 3AN: 1459270Hom.: 0 Cov.: 29 AF XY: 0.00000275 AC XY: 2AN XY: 726134
GnomAD4 genome AF: 0.00000663 AC: 1AN: 150906Hom.: 0 Cov.: 32 AF XY: 0.0000136 AC XY: 1AN XY: 73672
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:3
The p.A230P variant (also known as c.688G>C), located in coding exon 5 of the CHEK2 gene, results from a G to C substitution at nucleotide position 688. The alanine at codon 230 is replaced by proline, an amino acid with highly similar properties. This alteration was identified in multiple individuals diagnosed with breast cancer (Penkert J et al. Breast Cancer Res, 2018 08;20:87; Hauke J et al. Cancer Med, 2018 Apr;7:1349-1358). This alteration has also been reported in 1/1197 individuals from Greece, Romania, and Turkey undergoing evaluation for inherited cancer predisposition (Tsaousis GN et al. BMC Cancer, 2019 Jun;19:535). This alteration was reported as damaging in an mES cell-based assay of CHEK2 activity (Boonen RACM et al. Cancer Res, 2022 Feb;82:615-631). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
This missense variant replaces alanine with proline at codon 230 of the CHEK2 protein. Computational prediction tool suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). A functional study has shown this variant to be damaging to the kinase activity of the CHEK2 protein (PMID: 34903604). This variant has been reported in an individual affected with breast cancer with personal or family history suggestive of Li-Fraumeni syndrome (PMID: 30086788). This variant has also been identified in 1/251330 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Li-Fraumeni syndrome 2 Pathogenic:1
- -
not provided Uncertain:1
Observed in a patient with breast cancer and another undergoing hereditary cancer testing (Penkert 2018, Tsaousis 2019); Not observed at a significant frequency in large population cohorts (Lek 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 30086788, 31159747) -
Familial cancer of breast Uncertain:1
This sequence change replaces alanine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 230 of the CHEK2 protein (p.Ala230Pro). This variant is present in population databases (rs748636216, gnomAD 0.0009%). This missense change has been observed in individual(s) with a personal and/or family history of breast or ovarian cancer (PMID: 30086788, 30613976, 31159747). This variant is also known as c.817G>C (p.Ala273Pro). ClinVar contains an entry for this variant (Variation ID: 410020). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CHEK2 function (PMID: 34903604). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at